Related Experiment Video
Updated: Mar 26, 2026

Segmentation and Linear Measurement for Body Composition Analysis using Slice-O-Matic and Horos
Published on: March 21, 2021
Mid-adulthood cardiometabolic risk factor profiles of sarcopenic obesity
Jiantao Ma1, Shih-Jen Hwang1, Gearoid M McMahon1,2
1National Heart, Lung, and Blood Institute's Framingham Heart Study and Population Sciences Branch, Framingham, Massachusetts, USA.
Objective:
Midlife and contemporaneous cardiometabolic risk factors associated with sarcopenic obesity were examined.
Methods:
Utilizing BMI and sex-specific 24-h urinary creatinine excretion, 1,019 participants from the Framingham cohorts were categorized as non-sarcopenia non-obese (NSNO), non-obese sarcopenia, non-sarcopenic obesity, and sarcopenic obesity. Cardiometabolic risk factors were quantified by standard laboratory assessment cross-sectionally and 10, 20, and 30 years before sarcopenic obesity assessment.
Results:
NSNO, sarcopenia, obesity, and sarcopenic obesity accounted for 30.0%, 39.6%, 20.0%, and 10.4% of study participants, respectively. Cross-sectionally, participants with sarcopenic obesity had a higher proportion of hypertension, metabolic syndrome, and type 2 diabetes than those with NSNO or sarcopenia (all P < 0.03). Similar patterns were observed retrospectively at 10, 20, and 30 years. Compared with NSNO or sarcopenia, sarcopenic obesity was associated with a higher prevalence of type 2 diabetes at 10 years and hypertension and metabolic syndrome at all three time points before baseline (all P < 0.03). Individuals with sarcopenic obesity had more type 2 diabetes than those with obesity alone at baseline and 10 years prior (all P < 0.001).
Conclusions:
Older adults with sarcopenic obesity had more adverse midlife cardiometabolic risks, particularly diabetes 10 years earlier, which suggests the importance of early identification of risk factors associated with sarcopenic obesity.
Related Concept Videos
Obesity
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Coronary Artery Disease I: Introduction
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy

